Perflutren

Summary

Perflutren (CHEMBL1663) is an approved small molecule; indicated across 16 conditions including prostate adenocarcinoma and prostate carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 16 conditions
• Clinical trials: 55
• Chemistry: 188.02 Da · C3F8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1663
Name	Perflutren
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6432
ChEBI	CHEBI:31980
Molecular formula	C3F8
Molecular weight	188.02
InChIKey	QYSGYZVSCZSLHT-UHFFFAOYSA-N

SMILES: C(C(F)(F)F)(C(F)(F)F)(F)F

IUPAC name: 1,1,1,2,2,3,3,3-octafluoropropane

ChEBI definition: A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.

Also known as: Definity, Definity rt, DMP 115, DMP-115, DMP115, FS-069, FS069, Luminity, MRX-115, Optison, Perfluoropropane, Perflutren

Patent coverage: 7,111 distinct patent families (20,817 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

16 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
prostate adenocarcinoma	3	MONDO:0005082	EFO:0000673
prostate carcinoma	3	MONDO:0005159	EFO:0001663
myocardial infarction	2	MONDO:0005068	EFO:0000612
breast neoplasm	2	MONDO:0021100	MONDO:0007254
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
breast carcinoma	2	MONDO:0004989	EFO:0000305
chronic kidney disease	2	MONDO:0005300	EFO:0003884
intrahepatic cholangiocarcinoma	2	MONDO:0003210	EFO:1001961
kidney cancer	2	MONDO:0002367	MONDO:0002367
compartment syndrome	2	MONDO:0004001	MONDO:0004001
melanoma	1	MONDO:0005105	EFO:0000756
head and neck cancer	1	MONDO:0005627	EFO:0006859
lymphedema	1	MONDO:0019297	MONDO:0019297
osteosarcoma	0	MONDO:0009807	MONDO:0021054

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 55.

Phase distribution

Phase	Trials
Not specified	15
PHASE2	11
PHASE1	9
PHASE4	7
PHASE1/PHASE2	5
EARLY_PHASE1	4
PHASE3	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04643431	PHASE4	ACTIVE_NOT_RECRUITING	Risk Assessment of Carotid Plaques Using 3D Contrast-Enhanced Ultrasound
NCT06654804	PHASE4	RECRUITING	Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord Injury
NCT00918866	PHASE4	COMPLETED	A Study of Commercial DEFINITY® to Monitor the Effects of the Heart’s Pulmonary Artery Pressure
NCT02625428	PHASE4	COMPLETED	IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?
NCT03173716	PHASE4	COMPLETED	Real-Time Myocardial Perfusion Echocardiography in the ICU
NCT03544268	PHASE4	COMPLETED	Academic-Industrial Partnership for Translation of Acoustic Angiography
NCT03740997	PHASE4	COMPLETED	Study to Determine Safety and Dosage of OPTISON in Pediatric Participants
NCT00000140	PHASE3	COMPLETED	The Silicone Study
NCT01489176	PHASE3	COMPLETED	Regadenoson Real Time Perfusion Imaging Trial-Optison
NCT03571672	PHASE3	COMPLETED	DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
NCT05247541	PHASE2/PHASE3	COMPLETED	Diagnosing Compartment Syndrome With SHAPE vs Elastography
NCT02740868	PHASE2	RECRUITING	Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease
NCT05764642	PHASE2	ENROLLING_BY_INVITATION	A Study of Renal Microvessel Imaging for Chronic Kidney Disease
NCT06185972	PHASE2	RECRUITING	Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer
NCT00286559	PHASE1/PHASE2	WITHDRAWN	Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)
NCT01062178	PHASE2	COMPLETED	Efficacy of Ultrasound Contrast Agent to Assess Renal Masses
NCT01394926	PHASE2	TERMINATED	Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
NCT02061163	PHASE1/PHASE2	WITHDRAWN	Contrast-Enhanced Ultrasound in Human Crohn’s Disease
NCT02204917	PHASE1/PHASE2	COMPLETED	CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children
NCT02440334	PHASE2	COMPLETED	Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
NCT02672722	PHASE1/PHASE2	UNKNOWN	Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound
NCT03092089	PHASE2	COMPLETED	Sonothrombolysis in Patients With STEMI
NCT03199274	PHASE2	COMPLETED	Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
NCT03243942	PHASE2	COMPLETED	Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement
NCT03882359	PHASE1/PHASE2	COMPLETED	An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers
NCT04136912	PHASE2	TERMINATED	3-D Super Resolution Ultrasound Microvascular Imaging
NCT05328167	PHASE2	COMPLETED	Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
NCT05620290	PHASE1	RECRUITING	MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer
NCT06633601	PHASE1	RECRUITING	MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer
NCT07501650	PHASE1	RECRUITING	Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
NCT00186953	PHASE1	COMPLETED	Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
NCT00626873	PHASE1	COMPLETED	Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary
NCT02067884	PHASE1	TERMINATED	Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery
NCT04431648	PHASE1	UNKNOWN	Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Head and Neck Cancer
NCT04431674	PHASE1	COMPLETED	Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Breast Cancer
NCT05613946	PHASE1	COMPLETED	Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema
NCT07436364	EARLY_PHASE1	RECRUITING	Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy
NCT01751529	EARLY_PHASE1	COMPLETED	Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer
NCT02384473	EARLY_PHASE1	COMPLETED	Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma
NCT02671552	EARLY_PHASE1	WITHDRAWN	Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).